The role of RNA-carrying exosomes in synaptic physiology and in synucleinopathies
Objective: Our goals were: (i) to characterize the molecular mechanisms associated with the transfer of miRNAs from astrocytes to neuronal synapses via exosomes in transgenic…Impact of the severity of Parkinson’s disease on skin elasticity
Objective: To investigate changes in skin elasticity according to the severity of symptoms of Parkinson's disease. Background: Parkinson's disease (PD) is a neurodegenerative disease caused…Comparison of biospecimens for α-synuclein seed amplification assays in Parkinson’s disease: A Systematic Review and Network Meta-Analysis
Objective: We performed meta-analysis to determine the diagnostic and differential diagnostic value of α-syn SAAs for PD, and to investigate the optimal specimens. Background: Alpha-synuclein…Diagnostic Utility of Blood α-Synuclein in Parkinson’s Disease: A Systematic Review and Meta-analysis
Objective: The aims were to (1) explore the concentration differences of α-syn species in different blood components between PD and healthy controls (HC), and between…A staged screening paradigm to identify people at risk of Parkinson’s disease in the Parkinson’s Progression Markers Initiative
Objective: To identify people at risk of Parkinson’s disease (PD) using a staged-screening paradigm. Background: Early recognition of people with PD may be essential to…Decreased α-synuclein membrane-binding in the enteric nervous system as a marker of early pathology in Parkinson’s disease
Objective: The goal is to measure α-Synuclein (αSyn) membrane-binding in the enteric and central nervous system in Parkinson’s disease (PD) using both a novel, humanized…A vicious cycle of karyopherin abnormalities in synucleinopathies
Objective: This study aims to investigate the role of karyopherin abnormalities in the onset and progression of synucleinopathies. Background: Despite differences in clinical manifestations, Parkinson’s…Anle138b-P1-02: A randomised, double-blinded, placebo-controlled phase 1b study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of the oligomer modulator anle138b in Parkinson´s disease
Objective: To present first-in-patient data of the oligomer modulator anle138b (TEV-56286, emrusolmin) in patients with Parkinson’s disease (PD). Background: Synucleinopathies such as PD and Multiple…The induction of mitochondrial damage by alpha synuclein In Parkinson’s disease.
Objective: Alpha synuclein aggregation have been indicted in the process of neuronal cell loss in Parkinson's disease; however, there have been several hypothesis to explain…Parkinson’s disease in patients with Gaucher’s disease – causation or association?
Objective: To do a systematic review to find the risk of Parkinson's disease in patients with Gaucher’s disease. Background: Parkinson's disease (PD) is the second…
- « Previous Page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- …
- 60
- Next Page »